These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 37141481)
1. Teprotumumab-Induced Encephalopathy: A Rare Side Effect of a Novel Therapeutic. Yee MD; McCarthy J; Quinn B; Surani A WMJ; 2023 May; 122(2):134-137. PubMed ID: 37141481 [TBL] [Abstract][Full Text] [Related]
2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501 [TBL] [Abstract][Full Text] [Related]
3. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies. Winn BJ; Kersten RC Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408 [TBL] [Abstract][Full Text] [Related]
4. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study. Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699 [TBL] [Abstract][Full Text] [Related]
5. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series. Chu M; Sung J; Song M; Song A; Song J J Med Case Rep; 2022 May; 16(1):195. PubMed ID: 35538553 [TBL] [Abstract][Full Text] [Related]
6. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease. Kossler AL; Douglas R; Dosiou C J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685 [TBL] [Abstract][Full Text] [Related]
7. Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report. Ding AS; Mahoney NR; Campbell AA; Creighton FX Otol Neurotol; 2022 Feb; 43(2):e148-e152. PubMed ID: 34789694 [TBL] [Abstract][Full Text] [Related]
8. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists. Chern A; Dagi Glass LR; Gudis DA Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112 [TBL] [Abstract][Full Text] [Related]
9. A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface. Ugradar S; Kossler AL; Douglas R; Cockerham K J Neuroophthalmol; 2022 Mar; 42(1):26-34. PubMed ID: 35500236 [TBL] [Abstract][Full Text] [Related]
10. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy. Slentz DH; Nelson CC; Smith TJ Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706 [TBL] [Abstract][Full Text] [Related]
11. Teprotumumab: A Review in Thyroid Eye Disease. Nie T; Lamb YN Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673 [TBL] [Abstract][Full Text] [Related]
12. Ototoxicity and Teprotumumab. Highland J; Gordon S; Reddy D; Patel N Ann Otol Rhinol Laryngol; 2022 Aug; 131(8):910-913. PubMed ID: 34448414 [TBL] [Abstract][Full Text] [Related]
13. Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears? Bartalena L; Marinò M; Marcocci C; Tanda ML J Endocrinol Invest; 2022 Jul; 45(7):1455-1457. PubMed ID: 35403994 [No Abstract] [Full Text] [Related]
14. Teprotumumab for the Treatment of Active Thyroid Eye Disease. Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity. Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673 [TBL] [Abstract][Full Text] [Related]